Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» belantamab mafodotin
belantamab mafodotin
FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant
Endpoints
Wed, 08/5/20 - 11:24 pm
GSK
FDA
Multiple Myeloma
belantamab mafodotin
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
Wed, 07/29/20 - 10:54 am
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
FDA AdCom votes unanimously in favor of GSK myeloma drug, despite earlier agency skepticism
MedCity News
Tue, 07/14/20 - 11:22 pm
GSK
Multiple Myeloma
FDA
belantamab mafodotin
advisory panel
5 FDA approval decisions to watch in the 3rd quarter
BioPharma Dive
Thu, 07/9/20 - 11:09 am
FDA
Gilead Sciences
filgotinib
rheumatoid arthritis
GSK
belantamab mafodotin
Multiple Myeloma
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
MedCity News
Thu, 06/25/20 - 10:36 am
belantamab mafodotin
GSK
Multiple Myeloma
FDA
advisory panels
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
Xconomy
Sat, 06/13/20 - 11:27 pm
GSK
oncology
Zejula
niraparib
belantamab mafodotin
dostarlimab
immuno-oncology
GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight
Endpoints
Wed, 05/27/20 - 10:54 am
GSK
ASCO 2020
antibody-drug conjugate
belantamab mafodotin
Multiple Myeloma
FDA Speeds Up Examination of 5 Drugs with Priority Review
BioSpace
Thu, 02/13/20 - 12:24 am
FDA
priority review
capmatinib
Kite Pharma
KTE-X19
Eli Lilly
selpercatinib
GSK
belantamab mafodotin
Astex
C-DEC
GSK nabs speedy review for one of its top prospects
Fierce Biotech
Tue, 01/21/20 - 11:46 am
GSK
FDA
priority review
BCMA
belantamab mafodotin
relapsed or refractory multiple myeloma
GSK’s CEO Walmsley aiming for six new approvals in 2020
Pharmaforum
Tue, 01/14/20 - 10:07 am
GSK
Pharma CEOs
Emma Walmsley
JPMHC 2020
Zejula
Trelegy
daprodustat
belantamab mafodotin
GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind
Endpoints
Mon, 12/16/19 - 10:39 pm
GSK
Multiple Myeloma
belantamab mafodotin
clinical trials
GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test
Fierce Biotech
Fri, 08/23/19 - 10:14 am
GSK
anti-BCMA
Multiple Myeloma
belantamab mafodotin